Loading data for IRD — first visit, this takes a few seconds.

Opus Genetics, Inc. (IRD)

NasdaqCM: IRD · 实时价格 · USD

6.07

+0.34 (5.93%)

收盘价： Sep 11, 2026, 8:00 PM

6.02

-0.33%

盘后: 7:58 PM

提醒

Alert

股价、关键数字和最新消息，都在这一页。

暂无数据

买价	4.32
市值	503M
营收（TTM）	9.86M
净利润（TTM）	-108M
	0.58
	-1.29
	n/a
	-8.45
市净率（TTM）	-38.47
市销率（TTM）	50.98
财报日期	Nov 11, 2026

卖价	7.09
成交量	6,492,283
20日均量	1,991,675
开盘价	5.88
前收盘价	5.73
日内区间	5.41 - 6.24
52周区间	1.32 - 7.07
分析师	n/a
目标价	n/a
分红	n/a
除息日	n/a

关于 IRD

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The compa...

[阅读更多]

行业 Biotechnology

板块 Healthcare

上市日期 Nov 10, 2005

员工人数 27

交易所 NasdaqCM

股票代码 IRD

官网 https://opusgtx.com

公司完整简介

财务表现

2025年，Opus Genetics的营收为14.2M，较上一年的10.99M增长29.15%。净利润为-49.59M，下降-13.8%。

财务报表

财报意外

Opus Genetics 已于 Aug 6, 2026 发布季度财报：

营收为 $755K 低于预期 $0, ， -73.80% 同比下滑.
每股收益为 -0.08 超出预期 0.08, ， 33.33% 同比增长.

下次财报发布时间

Opus Genetics, Inc. 的下次财报预计于 Nov 11, 2026, 开盘前。
分析师预计营收为 ... 升级

股价变动原因

新闻

2天前 · MT Newswires

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Wednesday afternoon with the NYSE Healthcare Index and the State S

2天前 · Stocktwits

IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial

Researchers observed structural improvements in the retina in four of five patients being evaluated in a Phase 1/2 study

2天前 · InvestorsHub

Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data, Targets Potential Phase 3 Dosing in 2027

Opus Genetics (NASDAQ:IRD) reported positive low-dose Cohort 1 data from its Phase 1/2 BIRD-1 trial of OPGx-BEST1, alongside FDA alignment on potential pivotal endpoints and a development path that co...

1周前 · InvestorsHub

Opus Genetics shares rise 5.9% ahead of OPGx-BEST1 trial data

Opus Genetics Inc (NASDAQ:IRD) shares rose 5. 9% in pre-market trading ahead of the scheduled release of three-month topline data from Cohort 1 of its OPGx-BEST1 Phase 1/2 clinical trial.

1月前 · Zacks

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +6.67% and -75.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

第 1 页，共 2 页

Opus Genetics, Inc. (IRD)